The Science Journal of the Lander
College of Arts and Sciences
Volume 8
Number 1 Fall 2014
1-1-2014

Bioengineered Hearts
Rivky Loeb
Touro College

Follow this and additional works at: https://touroscholar.touro.edu/sjlcas
Part of the Cardiovascular System Commons, and the Molecular, Cellular, and Tissue Engineering
Commons

Recommended Citation
Loeb, R. (2014). Bioengineered Hearts. The Science Journal of the Lander College of Arts and Sciences,
8(1). Retrieved from https://touroscholar.touro.edu/sjlcas/vol8/iss1/13

This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar.
It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an
authorized editor of Touro Scholar. For more information, please contact touro.scholar@touro.edu.

-

Bioengineered Hearts
By: Rivky Loeb

Rivky graduated in June 2014 with a B.S. in biology.

Abstract
Heart disease is one of the highest causes for fatality in the world. Although many such diseases can be treated by
a heart transplant, this in itself can cause countless problems. Aside from the high demand for donor hearts, there
is the risk of the patient’s immune system rejecting the transplanted heart. A bioengineered heart would reduce
the need for donor hearts, and thus save countless lives. Finding a suitable scaffold, obtaining appropriate cells, and
ensuring that the tissue will function properly are the main focuses in creating an artificial heart.While most of the
studies done have been concentrated on creating cardiac tissue rather than the full organ, with the integration of
these aspects scientists are getting closer to the goal of engineering a fully functioning artificial heart.
Introduction

Heart failure is one of the most prevalent causes of death in the
world. There are many different diseases affecting the heart. For
many of them, the only answer is a heart transplant. Although this
has saved countless lives, transplants remain an imperfect solution.
Firstly, the list of people requiring new hearts is a long one, but the
amount of donor hearts available is few. Once a patient is approved
for a heart transplant, s/he is added to a waiting list, which is part
of a national allocation system run by the Organ Procurement
and Transplantation Network (OPTN). There are approximately
3,500 people on the list, and waiting times can range from about
six months to more than a year.
Even once a heart is found for the patient, and the transplant is
successful, the patient is still not out of danger. Although the heart
itself is healthy, it may not function properly in the recipient, causing a number of complications. One such concern is Primary Graft
Dysfunction, which is the most frequent cause of death in the first
30 days after a transplant (National Institutes of Health, 2012).
According to the OPTN, the one year survival rate for patients
in the U.S. aged 18-34 is almost 85%, with 75% 3 year survival
rate, and 66% five year. The 1, 3 and 5 year survival rate for recipients age 35-50 is slightly higher, at 88%, 81% and 74% respectively
(OPTN). Although these numbers are relatively high, one of the
main causes for heart transplant failure in the first year after the
transplant is due to the patient’s immune system rejecting the
foreign organ. To prevent this, immunosuppressant drugs are administered; however, this can cause damage to other organs such
as the kidneys and liver. High cholesterol, diabetes and cancer are
also some risks of the anti-rejection drugs (Bhimji, 2011). The gap
between the supply and demand for donor organs, as well as the
lifelong consequences for the patient, make the creation and implantation of a bioartificial heart a desirable alternative. While the
construction of a functional whole organ has not yet been accomplished, tissue engineering and regenerative medicine research
have obtained promising results for heart regeneration.
Bioengineers have been working on creating fully functioning organs that would eliminate the need for donors. This would solve
the issue of patients not receiving a heart in time, in addition to

getting rid of any concerns of rejection. There have been many
studies done all in the hope of answering the question, is growing
a new heart for a patient a foreseeable goal of the near future?
When trying to solve such a complicated issue there are numerous factors that must be taken into account, and many different
angles that the problem can be studied through. With the case
of the engineered heart, some of those factors include finding a
suitable base, or scaffold for the organ, deciding what kind of cells
would be appropriate for actually building the organ, and maturing the construct to develop some form of contractile and pump
function.

Methods

The information in this paper was obtained by analysis of scientific articles and research papers. Various online databases and
medical journals were used, accessed mostly via PubMed or the
Touro College database. Most of the information is based on experiments done using rat cells since this is the most practical way
of obtaining the large quantity of cells needed. Although the data
is not completely applicable to human cardiac cells, researchers
hope that these studies will provide insight into bioengineering of
human hearts.

Discussion

The first major issue in organ engineering is creating a scaffold
with enough elasticity, porosity, and strength to enable the cells
to grow correctly, thus resulting in a functioning organ or tissue.
The makeup of the scaffold is vital to the process because native
tissues contain different cell types, with each cell type having its
own unique three-dimensional (3-D) extracellular matrix environment, and mechanical properties. In addition, there are many other
structures that must be taken into account, such as blood vessels.
An ideal construct should display the functional and structural
properties of natural heart muscle, and therefore should be contractile, vascularized, and electrophysiologically stable. To recreate
such complexity in engineered tissues various approaches have
been used.
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Much of the research on cardiac tissue engineering that has been
done was focused more on small sections of tissue than on the
whole heart. However, this can be an important start to full organ
engineering, as the results of such studies can be incorporated
into studies dedicated to heart engineering.
Scientists have approached the issue of scaffolds from many different angles. In one such approach, cells are seeded on a degradable
scaffold on which they reorganize into engineered tissues.
A group of bioengineers set out to research different designs for
scaffolds to determine which would be most conducive to cardiac
tissue growth. They were able to create two layer scaffolds, with
fully interconnected pore networks, which aided in guiding the
pattern of cell growth. The material used was a synthetic elastomer poly(glycerol sebacate), known as PGS. This polymer was
chosen because of its ability to reproduce the mechanical stiffness and elasticity of the extracellular matrix. Additionally, PGS is
supportive of blood vessel formation, and cardiogenesis. Different
scaffolds were created with different properties, such as pore size,
and thickness. Two layer scaffolds 200μm in total thickness, with
interconnected pores were found to be the most effective for allowing heart cells to survive and form functional connections. PGS
scaffolds provided a platform for patterned cell distribution while
maintaining the geometric and mechanical properties of normal
heart muscle (Neal, et al., 2013). A similar study done at Duke
University used the flexible material PDMS (polyDimethylsiloxane) to create molds with elliptical pores. Such pores enabled the
enhanced diffusion of oxygen and nutrients to the cells (Liau, et
al., 2011).
In addition to the design for the scaffold, researchers must determine what kind of material should be used. One material, called
Poly(N-isopropylacrylamide) or PNIPAAm, is a polymer recently
emerging as a possibility due to its favorable properties. PNIPAAm
has controllable features and switchable surface properties, making
it an ideal option for scaffold formation. For example, PNIPAAm
has a lower critical solution temperature (LCST) of 32oC. This is
important because it will shrink and become hydrophobic at temperatures above the LCST, and hydrophilic at temperatures below.
Whereas hydrophobic surfaces are attractive for cell attachment,
detachment of cells and tissues from these templates requires
either an enzymatic reaction or physical scraping, both of which
can damage the cells.The use of PNIPAAm enabled controlled cell
detachment by adjusting the temperature (Tekin, et al., 2011).
Another advantage to using PNIPAAm is its dynamic properties.
Previously, micromolds were used to create microgels. However,
these scaffolds had static structures, meaning the surface properties and patterns could not be changed after fabrication. PNIPAAm
gel molds were able to be engineered to control 3-D organization
of the cells by mimicking the complex native tissue architecture.
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Additionally, the polymer is a hydrogel, which would enable blood
vessels to form in the organ. Coating surfaces in PNIPAAm served
to induce capillary network formation.This is especially important
for tissues to function properly (Tekin, et al., 2011).
Recently, a group of scientists experimented with adding single-wall carbon nanotubes (SWCNTs) to PNIPAAm to improve
the function of the base gel for use in myocardial repair. SWCNTs
are sheets of graphene rolled into a seamless cylinder. They have
remarkable electrical properties, which may even exceed the best
metals or semiconductors known, as experiments have shown
(McEuen, et al., 2002). They theorized that the SWCNTs would
improve the bioactivites and adhesion of the hydrogel to the cells.
After the cells were applied to the gel, it was observed that as
expected, cell adhesion and proliferation was about 1.71 times
greater in the PNIPAAm/SWCNT hydrogel than in the PNIPAAm.
The results indicated that the incorporation of SWCNTs greatly
enhanced the bioactivity of the PNIPAAm and aided in its functioning as a scaffold (Li, et al., 2014). Finding a suitable material for
the scaffold is one main step in the process of tissue engineering.
Another option recently being explored for use as scaffolds, are
decellularized organs. As mentioned previously, even if donor organs were not in short supply, the transplant recipient would still
be at risk of immune rejections and lifelong immunosuppression
treatment. To date, although numerous modern technologies have
been employed to fabricate new tissues, the creation of a functioning whole organ is still in progress. The use of decellularized
matrices would be a step in the right direction, as it would overcome the need for the bioengineer to artificially recreate the conditions for cell deposition. It would offer a microenvironment with
preserved natural geometry and vascular networks, which would
enable cells to grow in the correct patterns (Moroni , Mirabella,
2014).
In one such study, hearts were decellularized with detergents,
which preserved the underlying ECM, providing acellular, perfusable vascular architecture, and intact chamber geometry. All
cellular material which would induce an immune response, such
as cardiac and smooth muscle cells, DNA, RNA and soluble proteins, were removed. This left behind only the collagen, laminins
and other structural proteins as a scaffold. Fiber orientation and
composition remained intact, as did the arterial and venous basement membranes. As shown in figure 1, the detergent SDS was
successful in removing all cells, while the Triton detergent left cells
behind (Ott, et al., 2008).
The scaffold or decellularized organ now must be seeded with
cells.This leads to the next issue regarding tissue engineering: what
kind of cells should be used. Many researchers in the field use a
mixture of two or more cell types, such as endothelial precursor cells to line blood vessels, and muscle progenitors, which are
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Figure 1:
Hearts decellularized using different detergents. Asterisks indicate intact vascular network.
Source: Ott HC, et al. 2008

similar to stem cells, to seed the walls of the chambers. These can
be derived from induced pluripotent stem (iPS) cells- adult cells
genetically reprogrammed to an embryonic stem cell-like state,
which can be coaxed by scientists to become any kind of cell. This
is useful because these can be taken from the patient, and used
to make immunologically matched tissues (Maher, 2013). A team
from the University of Pittsburgh recently used iPS cells generated
from human skin cells to create precursor heart cells called MCPs.
The cells were placed on a decellularized scaffold, and grew and
developed into heart muscle.After 20 days, the tissue began showing cardiac muscle function (Discovery News, 2013).

growth. Additionally, by analyzing the density of the seeded cells,
they determined that the minimal cell seeding density necessary
to maintain construct structural integrity was achieved by using
1.4x106 cells per scaffold. For interconnected tissue structure,
8x106 cells per scaffold were required. From all the collected data,
the researchers concluded that structural and functional properties of constructs were improved by seeding polymer scaffolds
at high densities using rotating vessels. This study demonstrated
that dissociated cells cultured on 3D scaffolds under favorable
conditions were capable of forming engineered constructs with
features resembling those of native tissues (Carrier, et al., 1998).

Alternatively, as in a different study, heart cells were isolated from
neonatal rats and digested in a trypsin solution until dissociated
into a single cell suspension. Other steps were done to isolate the
cells, and at the end of this method 63% cardiomyocytes, 33% cardiac fibroblasts, 3-4% smooth muscle cells and 2-3% endothelial
cells were collected to be used to seed the scaffold (Neal, et at.,
2013).Tissues constructed from these heart cell mixtures showed
advanced structure, determining that creation of optimal cardiac
tissue constructs depends on a mix of non-monocytes and cardiac
monocytes (Zimmermann, et al., 2004).

Other favorable properties for cell growth were determined in
another study. Various factors were tested for their role in engineered heart tissue. High collagen content in the mixture yielded
tissue with higher stiffness, but less contractile force development.
Decreasing the collagen content yielded tissue with soft matrix
structure, but improved contractile properties.Additionally, the inclusion of horse serum was found to be beneficial for engineered
heart tissue development (Zimmermann, et al., 2004).

A group of scientists using similar neonatal cells performed experiments to determine the effect of different factors on the
growth of the cells in cultures and on the scaffold. For example,
by analyzing the gas and CO2 levels in different vessels, they were
able to determine what environment would be best for the cell

Once the scaffold is prepared and the cells cultured and seeded,
the next step is to observe and determine whether the cells will
behave as cardiac muscle cells.This includes being able to contract,
and electrically conduct signals. While full engineered heart transplants have not been perfected, scientists have been successful on
smaller scales. Biomedical engineers at Duke University were able
to grow a three dimensional human heart muscle that acted like
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natural tissue, in that it conducted electricity at about the same
speed as natural heart cells, and contracted appropriately (Duke
University, 2013). Using pluripotent embryonic stem cells permeated with fibroblasts, cardiac tissue was created with the capabilities of generating fast, uniform action potential propagation with
velocities ranging from 17.8cm/s to 24.1 cm/s, and contractile
force of 2mN (Liau, et al., 2011).
With the decellularization method, the recellularized hearts were
placed in bioreactors that mimicked the sensation of beating. A
combination of electrical signals was used to help synchronize the
cardiocytes seeded on the scaffold, along with physical beating
motions induced by a pump. After eight to ten days in the bioreactor the hearts were able to beat by themselves. However, when
the team implanted the engineered hearts into rats, none of the
hearts were able to perform the blood-pumping function at the
degree that is required of the heart (Maher, 2013).
In a study done in Tokyo, layered cell sheets coated with PNIPAAm
were created and implanted into the hearts of rats. At first the
beating of engineered tissue, at 96bpm, was relatively slow in comparison to host hearts, 332bpm; after four weeks it had gotten
stronger, though not as fast as the host tissue. A positive factor
was that neovascularization occurred in the tissue, which aided it
in functioning properly (Shimizu, et al., 2002).
In a different experiment, engineered heart tissue was created and
implanted onto an infarcted area in rat hearts. When evaluated
later, the engineered tissue showed electrical impulses in synch
with the native tissue. It was also evident that the implanted tissue had prevented further dilation and induced wall thickening of
infarcted myocardial segments. The epicardial activation of hearts
with the tissue graft was normal, indicating undelayed coupling of
the grafted tissue to the host tissue. The tissue was also able to
propagate electrical potentials (Zimmermann, et al., 2006). This
shows that tissue created in vitro can possibly function as natural
cardiac tissue in vivo.

Conclusion

Although a completely functioning heart has not yet been engineered, scientists are headed in the right direction. Using scaffolds
made of different materials and with different designs, they have
been able to stimulate cell growth in the right patterns for tissue
construction. Under the right conditions, the constructs behaved
in a manner similar to native cardiac tissue. Such engineered tissues have even been shown to function almost as well as natural
tissue in vivo. With the integration of these different aspects, and
advances in bioengineering, scientists are getting closer to the goal
of creating a fully functioning artificial heart.
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